Your browser doesn't support javascript.
loading
Pharmacokinetics of Clindamycin in Obese and Nonobese Children.
Smith, Michael J; Gonzalez, Daniel; Goldman, Jennifer L; Yogev, Ram; Sullivan, Janice E; Reed, Michael D; Anand, Ravinder; Martz, Karen; Berezny, Katherine; Benjamin, Daniel K; Smith, P Brian; Cohen-Wolkowiez, Michael; Watt, Kevin.
Afiliação
  • Smith MJ; Division of Pediatric Infectious Diseases, University of Louisville, Louisville, Kentucky, USA mjsmit22@louisville.edu.
  • Gonzalez D; Kosair Charities Pediatric Clinical Research Unit, University of Louisville, Louisville, Kentucky, USA.
  • Goldman JL; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Yogev R; Children's Mercy Hospital, Kansas City, Missouri, USA.
  • Sullivan JE; Northwestern University, Chicago, Illinois, USA.
  • Reed MD; Kosair Charities Pediatric Clinical Research Unit, University of Louisville, Louisville, Kentucky, USA.
  • Anand R; Akron Children's Hospital, Akron, Ohio, USA.
  • Martz K; EMMES Corp., Rockville, Maryland, USA.
  • Berezny K; EMMES Corp., Rockville, Maryland, USA.
  • Benjamin DK; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Smith PB; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
  • Cohen-Wolkowiez M; Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
  • Watt K; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Article em En | MEDLINE | ID: mdl-28137820
Although obesity is prevalent among children in the United States, pharmacokinetic (PK) data for obese children are limited. Clindamycin is a commonly used antibiotic that may require dose adjustment in obese children due to its lipophilic properties. We performed a clindamycin population PK analysis using data from three separate trials. A total of 420 samples from 220 children, 76 of whom had a body mass index greater than or equal to the 95th percentile for age, were included in the analysis. Compared to other metrics, total body weight (TBW) was the most robust measure of body size. The final model included TBW and a sigmoidal maturation relationship between postmenstrual age (PMA) and clearance (CL): CL (liters/hour) = 13.8 × (TBW/70)0.75 × [PMA2.83/(39.52.83+PMA2.83)]; volume of distribution (V) was associated with TBW, albumin (ALB), and alpha-1 acid glycoprotein (AAG): V (liters) = 63.6 × (TBW/70) × (ALB/3.3)-0.83 × (AAG/2.4)-0.25 After accounting for differences in TBW, obesity status did not explain additional interindividual variability in model parameters. Our findings support TBW-based dosing for obese and nonobese children.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Clindamicina / Modelos Estatísticos / Antibacterianos / Obesidade Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Clindamicina / Modelos Estatísticos / Antibacterianos / Obesidade Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2017 Tipo de documento: Article